IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1269 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (206 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  Abstract
 » Introduction
 » Case Report
 » Discussion
 »  References

 Article Access Statistics
    Viewed2865    
    Printed107    
    Emailed0    
    PDF Downloaded129    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 


 
 Table of Contents    
DRUG WATCH
Year : 2012  |  Volume : 44  |  Issue : 5  |  Page : 649-650
 

Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia


Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India

Date of Submission13-Oct-2011
Date of Decision30-May-2012
Date of Acceptance04-Jul-2012
Date of Web Publication31-Aug-2012

Correspondence Address:
Janardhanan C Narayanaswamy
Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.100406

Rights and Permissions

 » Abstract 

There are reports of de novo development or exacerbation of obsessive-compulsive symptoms in patients with schizophrenia treated with atypical antipsychotics, although this is widely debated. We report one such case where a patient with a primary diagnosis of schizophrenia, treated with olanzapine, developed de novo obsessive-compulsive disorder, with convincing evidence for its causality due to the drug.


Keywords: Obsessive-compulsive disorder, olanzapine, schizophrenia


How to cite this article:
Kulkarni G, Narayanaswamy JC, Math SB. Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia. Indian J Pharmacol 2012;44:649-50

How to cite this URL:
Kulkarni G, Narayanaswamy JC, Math SB. Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia. Indian J Pharmacol [serial online] 2012 [cited 2020 Nov 28];44:649-50. Available from: https://www.ijp-online.com/text.asp?2012/44/5/649/100406



 » Introduction Top


There are reports of de novo production or exacerbation of obsessive-compulsive symptoms (OCS) in patients with schizophrenia treated with atypical antipsychotics. [1],[2],[3] This issue has been debated owing to the lack of clarity about the causality of OCS. Since OCS occurs in a proportion of schizophrenia patients without the influence of any drug, it becomes difficult to substantiate the drug-induced causality of OCS. To establish directionality of causation, one needs to demonstrate in a longitudinal manner the occurrence of OCS after initiation of an atypical antipsychotic. We report one such case where a patient with a primary diagnosis of schizophrenia treated with olanzapine, developed de novo obsessive-compulsive disorder (OCD), with convincing evidence for its causality due to the drug.


 » Case Report Top


A 30-year-old married woman presented with symptoms such as suspiciousness, fearfulness, and significant hallucinatory behavior, which impaired her daily functioning, persisting for 3 years. She suspected that the neighbors had been trying to harm her through black magic. She had third person discussing type of auditory hallucinations with derogatory content. The Brief Psychiatric Rating Scale (BPRS) score was 48. A diagnosis of paranoid schizophrenia was made and she was started on olanzapine with 10 mg initially, later increased to 15 mg.

After 3 weeks of therapy, significant improvement was noted in her symptoms [hallucinations and suspiciousness (BPRS score: 10)]. At this point of time, she started having recurrent sexual thoughts and pathological doubts. She reported significant anxiety associated with these thoughts and felt them to be irrational and uncontrollable. The Yale Brown Obsessive Compulsive Symptoms (YBOCS) score was 18. She fulfilled a diagnosis of OCD with predominant obsessions. Due to the de novo emergence of severe obsessions, olanzapine was stopped and aripiprazole was started for psychotic symptoms. After 2 weeks of treatment with aripiprazole, patient's psychotic symptoms worsened within 5 weeks and the BPRS score reached 51. However, the OCD symptoms improved drastically with the YBOCS score reaching 4. Considering the worsening of psychotic symptoms, it was decided to restart olanzapine. While the patient's psychotic symptoms improved dramatically within 2 weeks of treatment, the obsessive symptoms reemerged with the same intensity as earlier. We started the patient on a trial of fluoxetine to 60 mg for OCD. At the end of 8 weeks after starting fluoxetine, OCD remitted and the YBOCS score reached zero. The patient is currently being followed-up for 2 years. There are no psychotic or OCD symptoms and her socio-occupational functioning is normal.


 » Discussion Top


Given the emergence of de novo obsessive-compulsive symptoms after starting olanzapine, their resolution after stopping the drug and re-emergence of the symptoms on re-challenge with olanzapine, it was concurred that OCD in this patient was induced by olanzapine. The use of Naranjo et al. adverse drug reaction probability scale [4] (score = 8) indicated that the adverse effects were probably related to olanzapine itself. Antiserotonergic properties of atypical antipsychotics have been implicated as the underlying mechanism causing obsessions, with an emphasis on their 5-HT 2A and 5-HT 2C receptor antagonism. [3],[5] In the case reported here, the obsessive thoughts emerged only after an optimal clinical dosage (15 mg/ day) was reached, suggesting a clear cut relationship between OCD symptom production and drug institution. Compared with the earlier reported cases, the use of a structured and validated scale to ascertain the causal relationship is an advantage in this report. Also this case follows a "removal-rechallenge" strategy to establish the same unlike the earlier reports. Since it is known that OCD may cooccur in a substantial proportion of schizophrenia patients, [6] this aspect must be considered in differentiation of drug-induced OCD symptoms due to the fact the treatment of schizophrenia is primarily with atypical antipsychotics. Close monitoring needs be exercised while starting atypical antipsychotics in schizophrenia since occurrence of OCS as a comorbid condition would affect the prognosis.

 
 » References Top

1.Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:333-46.  Back to cited text no. 1
[PUBMED]    
2.Alevizos B, Papageorgiou C, Christodoulou GN. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 2004;7:375-7.  Back to cited text no. 2
[PUBMED]    
3.Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 2011;41:2361-73.  Back to cited text no. 3
[PUBMED]    
4.Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 4
[PUBMED]    
5.Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 1997;9:1-17.  Back to cited text no. 5
[PUBMED]    
6.Rajkumar RP, Reddy YC, Kandavel T. Clinical profile of "schizo-obsessive" disorder: A comparative study. Compr Psychiatry 2008;49:262-8.  Back to cited text no. 6
[PUBMED]    



This article has been cited by
1 Biological treatments for obsessive-compulsive and related disorders
Xenia Borue,Mehak Sharma,Robert Hudak
Journal of Obsessive-Compulsive and Related Disorders. 2015;
[Pubmed] | [DOI]
2 Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature
Trehani M. Fonseka,Margaret A. Richter,Daniel J. Müller
Current Psychiatry Reports. 2014; 16(11)
[Pubmed] | [DOI]
3 Durch trimipramin induzierte zwangsstörung | [Trimipramine-induced obsessive-compulsive disorder]
Haas, I., Grohmann, R., Rüther, E., Degner, D.
Psychopharmakotherapie. 2013; 20(2): 82-87
[Pubmed]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow